Direct Oral Anticoagulants for Prevention of lEft ventRIcular Thrombus After Anterior Acute Myocardial InFarction - APERITIF

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 560 participants.

Also called NCT05077683

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 560 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05077683
  • EudraCT 2021-001534-19
Other papers using this trial's data
  • Low-Dose Rivaroxaban to Prevent Left Ventricular Thrombosis After Anterior Myocardial Infarction: The APERITIF Randomized Clinical Trial JAMA cardiology, 2026-04-01 DOI, PubMed 41739450, PMC12936965 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
France (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05077683. Randomized; no masking; primary purpose treatment. Start 2021-10-10 (actual); primary completion 2023-03-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Direct Oral Anticoagulants for Prevention of lEft ventRIcular Thrombus After Anterior Acute Myocardial InFarction - APERITIF
Acronym
APERITIF
Condition
Myocardial Infarction, Acute
Condition
Left Ventricular Thrombus
Intervention (Drug)
Rivaroxaban 2.5 MG [Xarelto]
Intervention (Drug)
DAPT strategy
Lead sponsor
Assistance Publique - Hôpitaux de Paris (class: other)

Record details

Record id
cardio:ct-nct05077683
Content hash
824e8c5736b10e06078e1e36f37372ec1a622a29c6747951ae50d5507c43e4b7